GLPwatch
Papers (10409)
Page 121 of 174, ranked by citation count.
- Management of obesity.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Weight Loss Pharmacotherapy: Current and Future Therapies.
- Patient Experience of Treatment with Tirzepatide for Weight Management: Exit Interviews from SURMOUNT-4.
- Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes.
- Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.
- GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations.
- Tirzepatide as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, and Fibrosis.
- A Review of First-Generation Obesity Medications.
- Mechanism of preventive effects of exendin-4 and des-fluoro-sitagliptin in a murine model of fructose-induced prediabetes.
- A phase I study comparing the pharmacokinetics of the biosimilar (RD12014) with liraglutide (Victoza) in healthy Chinese male subjects.
- Cardiovascular outcomes and mortality of bariatric surgery versus glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.
- Metabonomic analysis of the therapeutic effect of exendin-4 for the treatment of tBHP-induced injury in mouse glomerulus mesangial cells.
- Relationship of vascular complications and exenatide therapy failure in type 2 diabetic patients.
- Liraglutide improved glycaemic instability in a patient with diabetes with insulin antibodies.
- Elderly rats fed with a high-fat high-sucrose diet developed sex-dependent metabolic syndrome regardless of long-term metformin and liraglutide treatment.
- The mechanism of liraglutide on promoting osteogenesis via macrophages polarization under the inflammatory and oxidative stress in osteoporosis.
- Effectiveness of exenatide in Asian Indians in a clinical care setting.
- Once-weekly GLP-1R agonists: moving the goal posts.
- The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is it Advantageous?
- Liraglutide improves antioxidant defense in hearts of spontaneously hypertensive female rats independently of changes in blood pressure in a pre-clinical model of menopause.
- Influence of Buffering Capacity, pH, and Temperature on the Stability of Semaglutide: A Preformulation Study.
- Should family physicians prescribe medication for obesity? NO.
- Managing diabetes in patients with diabetes of long duration.
- Patterns of prescription and discontinuation of glucagon-like peptide-1 receptor agonists among patients with irritable bowel syndrome.
- Liraglutide attenuates autoimmune myocarditis by inhibiting NLRP3 and NF-κb pathways.
- Retinopathy risk factors in patients with type 2 diabetes on liraglutide.
- Oral GLP-1 Receptor Agonists for Weight Loss.
- Once-yearly device takes on daily and weekly diabetes drugs.
- Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review.
- Effects of all-trans retinoid acid and exendin-4 on islet transplantation in NOD mice.
- Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study.
- Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use.
- Analysis of Tirzepatide Acquisition Costs and Weight Reduction Outcomes in the United Kingdom: Insights from the SURMOUNT-1 Study.
- Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study.
- GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction.
- Liraglutide attenuates clozapine-induced mitochondrial dysfunction and improves energy metabolism in the brain of rats.
- Characteristics of WBN/Kob diabetic fatty rats supplemented with a fructose-rich diet as a metabolic syndrome model: response to a GLP-1 receptor agonist.
- Liraglutide modulates ALCAT1-Mediated cardiolipin remodeling to improve cardiac function in obese mice.
- Noninvasive quantitative evaluation of viable islet grafts using <sup>111</sup> In-exendin-4 SPECT/CT.
- Anti-inflammatory effect of glucagon-like Peptide-1 receptor agonist on the neurosensory retina in an acute optic nerve injury rat model.
- In persons with obesity, exercise plus liraglutide improved weight-loss maintenance vs. exercise or placebo.
- Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.
- Gender differences in weight gain during attempted and successful smoking cessation on dulaglutide treatment: a predefined secondary analysis of a randomised trial.
- Development of Flow-NMR Spectroscopy for Real-Time Monitoring and Kinetics Studies of Biomolecules: Case Study of Liraglutide Oligomerization.
- Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
- Screening for Inflammatory Markers Identifies IL-18Rα as a Potential Link between Exenatide and Its Anti-Inflammatory Effect: New Results from the Combat-JUDO Randomized Controlled Trial.
- Noninvasive Evaluation of GIP Effects on β-Cell Mass Under High-Fat Diet.
- Linoleic acid co-administration promotes oral delivery of exenatide-loaded butyrate-decorated nanocapsules.
- Pre-stroke weight loss by glucagon-like peptide 1 receptor and neuropeptide Y receptor Y2 activation improves post-stroke functional recovery in male diabetic mouse models.
- Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb.
- Effectiveness of Low Doses of Semaglutide on Weight Loss and Body Composition Among Women in Their Menopause.
- Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management.
- The etiopathogenesis and management of obesity: The quintessential quincunx.
- Activation of G-protein-coupled receptors and thyroid malignant tumors: the jury is still out.
- Design of Auto-Adaptive Drug Delivery System for Effective Delivery of Peptide Drugs to Overcoming Mucus and Epithelial Barriers.
- Engineered microenvironments and pancreatic islet-on-chips for screening sugar substitute and antidiabetic compounds.
- The evolving world of GLP-1 agonist therapies for type 2 diabetes.
- Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States.
- A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.